Welcome to our dedicated page for Veeva Sys news (Ticker: VEEV), a resource for investors and traders seeking the latest updates and insights on Veeva Sys stock.
Veeva Systems Inc. (NYSE: VEEV) is a cloud software company focused on the global life sciences industry, and its news flow reflects activity across commercial, R&D, quality, and corporate initiatives. Company announcements frequently highlight new product capabilities in its industry cloud for life sciences, including developments in Veeva AI, Vault CRM, Veeva Development Cloud, Veeva Quality Cloud, and solutions such as Veeva Environmental Monitoring and Veeva Basics.
Investors and industry professionals following VEEV news can see updates on strategic partnerships with major life sciences companies, such as long-term enterprise agreements and expanded use of Vault CRM by large pharmaceutical and biopharmaceutical organizations. Veeva also issues releases on its work with emerging biotechs, including adoption of Veeva Basics to standardize operations across clinical, regulatory, and quality.
Veeva’s news includes information on AI-driven capabilities like Veeva AI Agents for Vault CRM and PromoMats, covering agents such as Free Text Agent, Voice Agent, Pre-call Agent, Quick Check Agent, and Content Agent. These updates describe how the company embeds industry-specific AI into its applications to support productivity, compliance, and customer engagement in life sciences.
In addition, Veeva regularly publishes earnings results, financial outlooks, and capital allocation decisions, such as the authorization of a share repurchase program reported in an 8-K filing. The company also announces participation in investor conferences and provides details on its role as a Public Benefit Corporation. This news page aggregates these releases so readers can track product milestones, customer agreements, AI developments, financial updates, and corporate governance disclosures related to VEEV.
Veeva Systems (NYSE: VEEV) announced that over 75 biotechnology companies are now using Veeva Basics, their pre-configured and pre-validated software solution for clinical, regulatory, and quality operations. The company has introduced two new applications: Veeva CTMS Basics for clinical trial management and Veeva Submissions Publishing Basics for regulatory submissions.
The rapid adoption indicates a market shift from basic tools to comprehensive solutions that can scale with company growth. Available in North America and Europe, these solutions enable biotechs to deploy industry-leading software within weeks. Built on the Vault Platform, Veeva Basics allows customers to maintain current features and adapt their technology infrastructure as they expand.
Veeva Systems (NYSE: VEEV) has scheduled the release of its fiscal 2026 first quarter financial results for May 28, 2025, after market close. The company will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) on the same day to discuss the results. Prepared remarks will be posted to Veeva's investor relations website at approximately 1:05 p.m. PT. The quarter ended on April 30, 2025, and a webcast replay will be available on the company's website following the live event.
Veeva Systems (NYSE: VEEV) has announced its 2025 Veeva Commercial Summit, scheduled for May 13-14 in Boston. The event will feature keynote speakers from major pharmaceutical companies sharing strategies for unified customer engagement. CEO Peter Gassner will discuss Veeva's initiative to integrate AI into the Vault Platform and applications.
Key presentations include AstraZeneca's analytics standardization, Bayer's customer-centric engagement with Vault CRM, Boehringer Ingelheim's medical insights coordination, and Lilly's content ecosystem integration. Johnson & Johnson and Madrigal will showcase their data foundation implementations. The summit, one of North America's largest industry events for commercial and medical affairs leaders, will also feature emerging biotechs sharing go-to-market strategies.
Veeva Systems has announced Veeva AI, a major initiative adding artificial intelligence capabilities to their Vault Platform and applications. The AI enhancement aims to boost productivity across clinical, regulatory, safety, quality, medical, and commercial sectors through AI Agents and AI Shortcuts.
The platform will feature application-specific AI Agents that understand context, include safeguards, and securely access Veeva data. Users can customize these agents and create new ones for specific needs. AI Shortcuts allow users to set up personal automations for common tasks.
Key features include:
- LLM-agnostic design supporting major language models
- Flexible deployment with Veeva-supplied or customer-specific LLMs
- Secure data handling for each customer
- Simple subscription fee structure
The first release is scheduled for December 2025, with licensing at the Vault level.
Veeva Systems (NYSE: VEEV) has announced SiteVault CTMS, a new clinical trial management system designed to enhance research site efficiency. The system will be integrated with SiteVault eISF and SiteVault eConsent, enabling comprehensive trial management within a single platform.
The solution features bidirectional data flow integration with sponsors using Veeva's Clinical Platform, aimed at reducing manual processes. Notably, SiteVault CTMS will be free for sites managing up to 20 concurrent active studies, representing over 90% of research sites.
The initial release is planned for August 2025, with live demonstrations scheduled during ACRP 2025 in New Orleans (April 24-27).
Veeva Systems (NYSE: VEEV) announced that Indero, formerly Innovaderm Research, has successfully completed its 40th study implementation using Veeva RTSM (Randomization and Trial Supply Management). This milestone demonstrates the successful standardization of Indero's clinical trial operations using Veeva's RTSM platform.
The specialized CRO has leveraged Veeva RTSM's advanced capabilities to enhance operational efficiency, improve process consistency, and streamline trial execution. Eric Hardy, senior director of biometrics at Indero, highlighted that the platform has enabled more efficient processes and better collaboration, ultimately accelerating the path to bringing therapies to market.
The partnership between Indero and Veeva has focused on developing and implementing standardized processes for long-term clinical trial success, with Veeva's enterprise standard RTSM approach contributing to greater efficiency and reliability in study execution.
Veeva Systems (NYSE: VEEV) and Boehringer Ingelheim have successfully launched the 'One Medicine Platform' powered by Veeva Development Cloud, marking a significant milestone in their collaboration announced in March 2022. The platform unifies data and processes across clinical, regulatory, and quality functions.
As one of the top 20 biopharma companies, Boehringer Ingelheim is leveraging this unified platform to streamline product development, optimize trial efficiency, and enhance collaboration with research sites. The implementation enables seamless data connectivity across functions, aiming to accelerate the delivery of new treatments for currently incurable diseases.
The Veeva Development Cloud serves as the technology foundation, integrating clinical, quality, regulatory, and safety applications to simplify end-to-end business processes and deliver process excellence.